Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant type III collagen bladder repair agent vs sodium hyaluronate for cystitis
ChiCTR2300074102Phase 3Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of recombinant human type III collagen in cystitis and Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS) (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: Treatment response rate at follow-up 1 week after last treatment. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
recombinant human type III collagen
03
Conditions
cystitisInterstitial Cystitis-Bladder Pain Syndrome (IC/BPS)
Beyond the preview
Go deeper on ChiCTR2300074102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074102.